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Abstract
Hemolytic uremic syndrome (HUS) is a systemic and potentially fatal complication of gastroenteritis
secondary to Shiga toxin-producing enterohemorrhagic Escherichia coli (EHEC) infection characterized by
microangiopathic hemolytic anemia, thrombocytopenia, and acute renal damage. Shiga toxin (Stx), the toxin
principle in HUS, is produced locally within the gut following EHEC colonization and is disseminated via the
vasculature. Clinical development of HUS currently has no effective treatment and is a leading cause of renal
failure in children. Novel post-exposure therapies are currently needed for HUS; therefore, the purpose of this
study was to investigate the efficacy of a Stx receptor mimic probiotic in a porcine model of HUS. Edema
disease, an infection of swine caused by host adapted Shiga toxin-producing Escherichia coli (STEC) and
mediated by Shiga toxin 2e (Stx2e), shares many pathogenic similarities to HUS. In this study, three-week old
piglets were inoculated with STEC and 24 hours later treated twice daily with a probiotic expressing an
oligosaccharide receptor mimic for Stx2e to determine if the probiotic could reduce intestinal toxin levels.
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Therapeutic use of a receptor mimic probiotic
reduces intestinal Shiga toxin levels in a piglet
model of hemolytic uremic syndrome
Shannon J Hostetter1*, Amy F Helgerson2,4, James C Paton3, Adrienne W Paton3 and Nancy A Cornick2
Abstract
Background: Hemolytic uremic syndrome (HUS) is a systemic and potentially fatal complication of gastroenteritis
secondary to Shiga toxin-producing enterohemorrhagic Escherichia coli (EHEC) infection characterized by
microangiopathic hemolytic anemia, thrombocytopenia, and acute renal damage. Shiga toxin (Stx), the toxin
principle in HUS, is produced locally within the gut following EHEC colonization and is disseminated via the
vasculature. Clinical development of HUS currently has no effective treatment and is a leading cause of renal
failure in children. Novel post-exposure therapies are currently needed for HUS; therefore, the purpose of this
study was to investigate the efficacy of a Stx receptor mimic probiotic in a porcine model of HUS. Edema disease, an
infection of swine caused by host adapted Shiga toxin-producing Escherichia coli (STEC) and mediated by Shiga toxin
2e (Stx2e), shares many pathogenic similarities to HUS. In this study, three-week old piglets were inoculated with STEC
and 24 hours later treated twice daily with a probiotic expressing an oligosaccharide receptor mimic for Stx2e to
determine if the probiotic could reduce intestinal toxin levels.
Methods: Piglets were orally inoculated with 1010 CFU of STEC strain S1191 eight days after weaning. Beginning
day 1 post-inoculation, piglets were treated orally twice daily with 5 × 1011 CFU of either the receptor mimic
probiotic or a sham probiotic for 10 days. Intestinal Stx2e levels were assessed daily via Vero cell assay. The
efficacy of the probiotic at reducing intestinal Stx2e, vascular lesions, and clinical disease was evaluated with
repeated measures ANOVA and Fisher’s exact test as appropriate.
Results: The probiotic significantly reduced intestinal Stx2e, as reflected by decreased fecal toxin titers on days
3–8 post-inoculation (p < 0.01). Despite this reduction in intestinal toxin levels, however, the probiotic failed to
reduce the incidence of vascular necrosis in target organs and had no effect on clinical disease.
Conclusions: The data suggest that post-exposure treatment with a Stx-binding probiotic is effective in reducing
intestinal toxin burden. Future studies could target this approach for possible development of post-exposure
interventions.
Keywords: Shiga toxin-producing Escherichia coli, Probiotic, Therapy, Hemolytic uremic syndrome, Edema disease,
Animal model
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Background
Enterohemorrhagic Escherichia coli (EHEC), classically of
serotype O157:H7, cause sporadic cases as well as out-
breaks of food borne illness characterized by hemorrhagic
colitis [1]. Ruminants are the primary reservoir for EHEC,
and contamination of either produce or meat with fecal
matter from carriers serve as the primary source of infec-
tion [2]. A small percentage of patients (typically 5-15%)
with diarrhea secondary to EHEC infection develop a
systemic and potentially fatal complication known as
hemolytic uremic syndrome (HUS), characterized by the
triad of microangiopathic hemolytic anemia, thrombo-
cytopenia, and acute renal damage. Historically, HUS has
been more prevalent in children under the age of 10 and
the elderly, and it remains the leading cause of renal fail-
ure in children in the United States [1,3-5]. More recently,
a large outbreak of gastroenteritis and HUS in Germany
caused by an atypical enteroaggregative E. coli that pro-
duced Shiga toxin (serotype O104:H4), was characterized
by a higher prevalence of HUS in adults versus children.
In this particular outbreak, 88% of the patients who devel-
oped HUS were adults [6-8]. At present, there is no
known method to predict which patients with diarrhea
caused by EHEC will develop HUS, and no single effective
treatment for the disorder once it is diagnosed. Currently,
HUS treatment involves fluid therapy, dialysis, and man-
agement of coagulation disorders; antimicrobial therapy,
however, remains controversial [9-11].
Although the pathogenesis is multifactorial, Shiga
toxin (Stx) produced by EHEC is the principal medi-
ator of HUS. EHEC that produce Stx1, Stx2, or both
toxins have been associated with HUS development.
Epidemiologic evidence and data from animal models
show that strains producing Stx2 only are more likely
to cause severe disease [12,13]. The preferred receptor
for Stx1, Stx2, and most of its variants is globotriaosyl-
ceramide (Gb3); globotetraosylceramide (Gb4) is the
preferred receptor of Stx2e, the Stx2 variant which is
primarily associated with edema disease of swine [14].
Following EHEC colonization, Stx is produced locally
within the intestine, and then crosses the intestinal
mucosa and vascular endothelium to gain access to the
bloodstream. Although the exact mechanism for systemic
absorption of Stx is unknown, recent evidence suggests
absorption across the epithelium occurs via a transcellular
pathway and is increased under microaerobic conditions
[15]. Once the toxin reaches the blood, it binds the
receptor on the surface of vascular endothelial cells in
key target organs (kidney, brain) and is internalized [16].
Toxin internalization within endothelial cells results in
inhibition of protein synthesis, leading to cell death [4].
Many experimental approaches to the treatment of
EHEC infection and/or HUS have been explored. One
potential therapeutic approach for HUS is to neutralize
the activity of Stx and several compounds have been
developed for that purpose, including oral synthetic
receptor mimics and specific anti-Stx antibody [17-20].
In this fashion, a probiotic that expresses Stx receptor
mimics on its surface was developed for treatment of
active EHEC infection [21]. The advantage of this particu-
lar probiotic is its ability to bind and absorb Stx within the
intestinal lumen, therefore potentially increasing its utility
as a post-exposure therapeutic agent. The probiotic is a
recombinant E. coli R1 strain (CWG308) that contains a
plasmid (pJCP-Gb3) encoding two Neisseria sp. galactosyl-
transferase genes that when expressed, create a cell surface
mimic of the Stx receptor. The binding capacity of this
recombinant strain for either Stx1 or Stx2 is approxi-
mately 10,000× greater than that of SYNSORB Pk (a syn-
thetic carbohydrate receptor mimic previously developed
for treatment of STEC infection), and this efficacy has
been demonstrated by several in vivo protection studies in
mice [19,21-23]. This particular construct was effective at
neutralizing most of the Stx2 variants; however, it was less
efficacious against Stx2e, which binds preferentially to
Gb4. As a result, a new recombinant strain that expressed
surface Gb4 was created as a potential probiotic strain for
use in the prevention of edema disease of swine [22].
Edema disease, an infection of weaned swine caused
by host-adapted strains of E. coli, has been adapted by
our laboratory as an animal model of systemic EHEC
disease in human beings [24,25]. The edema disease
model has several advantages over other models of
HUS, the most outstanding of which is that it is a natur-
ally occurring disease. Edema disease and HUS share
similar early events in their pathogeneses, including lo-
calized production of toxin in the gut, toxin transloca-
tion across gut epithelium, and dissemination to target
organs via the bloodstream [24,25]. Additionally, as in
human EHEC infections, not all Shiga-toxin producing
Escherichia coli (STEC) inoculated swine develop sys-
temic disease; the majority of pigs undergo an uncompli-
cated recovery from the diarrhea phase. Other advantages
include a similar time course of pathogenic events
manifested by a prodromal diarrhea phase with delayed
development of systemic complications [24]. In this
model, approximately 30% of STEC challenged swine
succumb to clinical disease secondary to Shiga toxemia,
characterized by subcutaneous edema, neurological signs
and/or sudden death.
We hypothesized that treatment with the probiotic
expressing surface globotetraose would bind and trap
Stx2e within the intestinal lumen, thereby reducing
systemic toxin absorption and preventing clinical edema
disease. The primary purpose of this study was to assess
the ability of this Stx receptor–mimic probiotic to
reduce fecal Shiga toxin in a naturally occurring STEC
infection when administered during active infection. A
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secondary goal was to test the efficacy of the probiotic at
preventing clinical disease.
Methods
Bacterial strains
S1191 is an STEC strain isolated from a pig with edema
disease. This strain belongs to serotype O139, is resistant
to chloramphenicol, and produces Stx2e, hemolysin,
F18ab fimbriae and heat-stable enterotoxin B. Strain 123
is a non-pathogenic E. coli, serogroup O143, isolated
from a healthy pig. Inocula were prepared as described
previously [24].
Creation of the probiotic strain, an E. coli R1 deri-
vative expressing surface GalNAcβ(1→ 3)Galα(1→ 4)
Galβ(1→ 4)Glc (globotetraose), has been described in
detail previously [22]. Briefly, three Neisseria sp. glyco-
syltransferase genes (lgtC, lgtE, and lgtD) and a UDP-
GalNAc-4-epimerase gene (gne) were cloned into the
plasmid vector pK184 to create plasmid pGb4 and
inserted into a derivative of E. coli R1 (CWG308). This
strain has a waaO mutation in the outer core lipopolysac-
charide (LPS) biosynthesis locus that results in production
of a truncated LPS core terminating in glucose. Expression
of the plasmid-encoded glycosyltransferase genes results
in linkage of GalNAcβ(1→ 3)Galα(1→ 4)Galβ(1→ 4)
onto the terminal glucose. The sham strain is the E. coli
derivative R1 (CWG308) with the plasmid vector pK184
only. The treatment and sham strains were grown
overnight in tryptic soy broth (TSB) plus kanamycin
(30 μg/ml) and IPTG (20 μg/ml), concentrated 100×
and re-suspended in TSB containing 10% NaCO3, 20%
sucrose and 21% glycerol. Treatments were stored at -80C
and thawed just prior to use.
Reproduction of clinical edema disease
Animal experiments were carried out in accordance with
the Iowa State University Animal Care and Use Commit-
tee. The study design proposed here to reproduce clinical
edema disease follows a previously described protocol and
is outlined in Table 1 [24]. Briefly, two week-old crossbred
pigs were acclimated to a high soy protein diet for one
week prior to challenge [26]. Pigs were orally inoculated
with 1010 CFU of STEC strain S1191 eight days after
weaning. Control pigs received 1010 CFU of the non-
pathogenic E. coli strain 123. Separate rooms in the same
housing facility were used for each treatment group. Pigs
were monitored twice daily for clinical signs of edema
disease (subcutaneous edema, recumbency or neurological
disturbances such as ataxia, circling or sudden death). Pigs
that developed neurological signs were euthanized by an
intravenous overdose with barbiturate. Pigs that failed to
develop neurological signs were euthanized at the termin-
ation of the study (14 days post-inoculation). All pigs
underwent a complete necropsy, with inspection of major
organs for gross lesions and collection of tissue samples
stored in 10% neutral buffered formalin taken from ileum
(section taken approximately 1 m proximal to ileocecal
valve) and brainstem (section taken at rostral medulla) for
histology. Fixed tissues were embedded in paraffin and
sectioned at 5 μm. Histologic evaluation of tissues for
vascular lesions consistent with edema disease followed
an established protocol [24,27]. Briefly, hematoxylin and
eosin stained sections of ileum and brainstem were exam-
ined by a board certified veterinary pathologist (SJH)
blinded to the treatment groups for qualitative evidence of
vascular necrosis in arterioles. Scores were considered
positive if two or more necrotic vessels were identified per
complete tissue section.
Treatment with the probiotic
Pigs inoculated with STEC strain S1191 were treated
with either E. coli CWG308 containing the plasmid pGb4
(probiotic) or CWG308 containing the vector pK184
only (sham). Individual pigs were orally dosed with
5 × 1011 CFU of either strain twice daily for 10 days
beginning day 1 post-inoculation.
Determination of Stx2e in feces
Feces were collected daily from control and STEC-
inoculated pigs on days 1–10 post-inoculation, and
stored at 4°C until processing. Stx2e concentrations were
assessed using a Vero cell assay as described previously
[24]. Briefly, samples were diluted two-fold in PBS and
added to monolayers of Vero cells in microtiter plates.
Toxin titers were expressed as the log of the reciprocal
of the greatest dilution that resulted in ≥ 50% Vero cell
Table 1 Experimental design to assess the effect of a probiotic expressing a Shiga toxin receptor mimic on the
incidence of edema disease
Experimental group Number of pigsa Pig age at inoculation Inoculation strain Treatment
Probiotic 30 24-26 days S1191c CWF308 (pJCPGb4)
Sham 30 24-26 days S1191c CWF308
Negative control 10 24-26 days 123b None
aEach group represents the cumulative number of pigs from three separate experimental replications. bNon-pathogenic E. coli strain. cSTEC strain.
Three week old piglets were orally inoculated with either pathogenic STEC strain 1191 (probiotic and sham groups) or non-pathogenic E. coli strain 123 (negative
control group). STEC inoculated pigs were treated with either a Shiga toxin 2e receptor mimic probiotic (probiotic group) or a sham probiotic strain which lacked
the receptor mimic (sham group). Treatment was administered twice daily, and was initiated 24 hours post-inoculation with the STEC strain.
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death. Specificity of the titers for Stx2e was confirmed
by neutralization with anti-Stx2e antibody.
Statistical analysis
Comparison of fecal toxin titers was performed using a
two way repeated measures ANOVA with an unweighted
means analysis (Prism, Graphpad software, Inc, La Jolla,
CA). Bonferroni post hoc test was used to compare group
differences on specific days. For all analyses, a P value
< 0.05 was considered statistically significant. Incidences
of vascular lesions and clinical disease between probiotic
and sham groups were compared using Fisher’s exact test.
Results
Bacterial colonization
STEC strain 1191 was recovered from feces of all chal-
lenged pigs (probiotic and sham groups) at both 2 and
5 days post inoculation. None of the negative control
pigs were positive for STEC at either time-point. The
probiotic E. coli strain CWG308 (pJCPGb4) was recov-
ered from all pigs in the probiotic treated group at both
2 and 5 days post inoculation.
Fecal toxin titers
Stx titers were measured daily in feces to assess the effi-
cacy of the probiotic at adsorbing Stx within the intes-
tinal lumen. Increases in fecal Stx titers in both the
sham and probiotic treated STEC inoculated groups
were detectable beginning day 1 post inoculation, and
peaked on days 5–7 post inoculation (Figure 1A). Treat-
ment with the probiotic significantly reduced fecal Stx2e
levels compared to the sham treated group on days 3–8
post-inoculation (p < 0.01, repeated measures ANOVA
with Bonferroni post hoc test, Figure 1A). None of the
control pigs had detectable Stx2e in their feces at any
time point throughout the study (data not shown).
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Figure 1 Effect of twice daily treatment with a probiotic expressing globotetraose, initiated 24 hours post-inoculation with Shiga
toxin-producing Escherichia coli, on mean fecal Shiga toxin 2e titers in piglets. Globotetraose is the preferred receptor for Stx2e. A).
Treatment with the probiotic significantly reduced titers compared to sham treated pigs on days 3–8 post inoculation (*, P < 0.01, **P < 0.001,
repeated measures ANOVA with Bonferroni post hoc test). Error bars indicate SEM. B). Although fecal Shiga toxin levels were reduced overall
within the probiotic group, pigs that developed clinical edema disease had higher levels of fecal Shiga toxin, similar to the sham treated group.
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Clinical disease
Seven out of sixty pigs inoculated with the STEC strain
1191 developed clinical edema disease and no differ-
ences were clinically detected between probiotic or sham
treated pigs (Table 2). Of the pigs with clinical edema
disease, three exhibited neurological signs prior to euthan-
asia and four were found dead. In summary, three of the
seven clinically affected pigs were in the probiotic treat-
ment group, and four were in the sham group resulting in
an overall disease incidence of 10% in the probiotic group
and 13% in the sham group. None of the ten pigs inocu-
lated with the non-pathogenic E. coli strain 123 developed
clinical signs of edema disease or died.
Comparison of fecal toxin titers between clinical and
non-clinical pigs
Fecal toxin titers in clinical pigs were compared with
titers in non-clinical pigs in both the sham and probiotic
treatment groups (Figure 1B). Since all pigs that developed
edema disease fell ill prior to day 8 post inoculation, fecal
titers are not available for these pigs beyond day 7 post in-
oculation. Although treatment with the probiotic reduced
fecal toxin titers overall, those pigs treated with the pro-
biotic that developed clinical disease had, on average, toxin
titers similar to the sham treated group.
Vascular lesions
Brainstem and ileum were assessed postmortem for
vascular evidence of Shiga toxemia. Histologic evidence
of edema disease (vascular necrosis in two or more
vessels per tissue section) was not detected in any of the
ten pigs inoculated with the non-pathogenic E. coli strain
(Figure 2, Table 2). Probiotic treated pigs had vascular
lesions in 56.7% (17/30) of ilea and 36.7% (11/30) of
brainstems, whereas sham-treated pigs had vascular
lesions in 63.3% (19/30) of ilea and 56.7% (17/30) of
brainstems. There was a trend for probiotic treatment
to reduce vascular lesions in brainstem (p = 0.098); how-
ever, the overall incidence of vascular lesions was not
statistically significant between probiotic and sham
treated groups for either tissue (NS, Fisher’s exact test).
Discussion
The probiotic strain expressing globotetraose used in this
study was designed specifically to bind and neutralize
Stx2e, the toxic principal of piglet edema disease. This
construct was effective at neutralizing 98.4% of Stx2e cyto-
toxicity in vitro [22]. The dose of probiotic and frequency
of administration used here were extrapolated from previ-
ous studies with a similar probiotic expressing a surface
Gb3 mimic in a mouse model of STEC infection [23].
Here we show that post-exposure treatment twice daily
with the probiotic was effective at reducing the fecal Stx2e
in STEC inoculated piglets. Fecal toxin titers were signifi-
cantly reduced by day three of probiotic administration,
and remained lower for several days. Reduction of intes-
tinal Stx may be a first line of defense in HUS prevention
for EHEC infected patients. Despite the favorable reduc-
tion in intestinal Stx, treatment with the receptor mimic
probiotic failed to reduce the incidence of both vascular
lesions in target organs and clinical disease in STEC inoc-
ulated swine, indicating systemic absorption of Shiga toxin
still occurred. While not statistically significant, the inci-
dence of vascular lesions in brainstems of probiotic treated
pigs was less than that of sham treated pigs. This subtle
trend towards lower disease incidence may warrant fur-
ther studies to increase the power to experimentally detect
lesion differences. Interestingly, those pigs that developed
clinical disease within the probiotic group had, on average,
higher fecal toxin titers than subclinical pigs within this
group, with the average toxin titers of clinical pigs
approaching those of the sham treated groups on days
2–6 post inoculation. This could indicate a failure of the
probiotic to reduce toxin titers in those pigs that broke
with clinical disease, despite an overall reduction in
toxin titers within this treatment group.
In contrast to our findings here, several studies in mouse
models have shown the efficacy of various probiotic
strains at preventing disease caused by EHEC. Import-
antly, however, the probiotics used in these studies were
administered prior to colonization. For example, Leatham
et al. showed that certain commensal E. coli strains were
efficacious at preventing growth of an E. coli O157:H7
Table 2 Incidences of clinical disease and vascular lesions in pigs inoculated with Shiga toxin-producing Escherichia
coli and treated with a probiotic strain expressing a Shiga toxin receptor mimic vs. a sham strain lacking the receptor
mimic
Experimental group Number
of pigsd
Incidence of
clinical disease
Incidence of vascular
lesions in brainstem
Incidence of vascular
lesions in ileum
Probiotica 30 3/30 11/30 17/30
Shamb 30 4/30 17/30 19/30
Negative controlc 10 0/10 0/10 0/10
aInoculated with STEC strain, treated with probiotic. bInoculated with STEC strain, treated with sham. cInoculated with non-pathogenic E. coli strain, no treatment.
dSum of three experimental replicates.
Negative control pigs were inoculated with a non-pathogenic, commensal E.coli strain. Probiotic treatment had a tendency to reduce the incidence of vascular
lesions in brainstem (p = 0.098); however, treatment with the receptor mimic probiotic did not significantly reduce the incidences of clinical disease or vascular
lesions (Fisher’s exact test).
Hostetter et al. BMC Research Notes 2014, 7:331 Page 5 of 8
http://www.biomedcentral.com/1756-0500/7/331
strain in the streptomycin-treated mouse model of
EHEC infection [28]. Similarly, certain bifidobacterial
strains were able to prevent mortality in a gnotobiotic
mouse model of EHEC infection when administered
seven days prior to inoculation with the EHEC strain
[29]. While these probiotics ameliorated disease caused
by EHEC via inhibition of colonization, other probiotics
are thought to confer protection via other mechanisms,
such as suppression of virulence factor production or
alteration of the host immune response [30,31]. For
example, in a recent study by Eaton et al., treatment with
the probiotic Lactobacillus reuteri suppressed disease in a
mouse model of EHEC infection, but had only a minimal
effect on colonization. The authors propose that the
probiotic may have affected production of Stx2, but that
further investigation was required to confirm the mechan-
ism [31]. Based on these studies, we anticipated that the
receptor mimic probiotic would be efficacious at prevent-
ing systemic disease in our pig model. However, one
important difference between our study and those de-
scribed above is the timing of probiotic administration.
The probiotics used in the previous studies were most
efficacious when administered prior to colonization with
EHEC, and would therefore have limited therapeutic
utility in the treatment of existing infections. The pro-
biotic strain used in our study was given 1 day post
STEC inoculation to investigate its efficacy in a post-
exposure setting - similar to that which might be experi-
enced during outbreaks of foodborne illness secondary
to EHEC. Preemptive treatment of individuals during
EHEC outbreaks may not be practical, given their spor-
adic nature. Our receptor mimic probiotic was designed
specifically to bind Stx within the gut; therefore, we
hypothesized that it would be useful as a post-exposure
therapy and our experimental design reflected this. We
speculate that the receptor mimic probiotic would likely
have been more effective at preventing systemic disease
had it been administered prior to STEC inoculation,
similar to previous studies.
In mice, treatment with a similar probiotic expressing
a Gb3 mimic was protective against fatal systemic com-
plications of infection with human-derived EHEC [21].
There are several differences between the mouse studies
and the current study that may have influenced treat-
ment outcome. The affinity of the Gb4 mimic bacterium
for Stx2e is not quite as high as that of the previously
described Gb3 mimic for other members of the Stx
family that was used in the mouse studies [22]. This
reduced affinity may have resulted in sub-optimal reten-
tion of Stx2e in the gut lumen. A further disparity be-
tween these studies is the timing of probiotic treatment.
In mice, treatment with the probiotic strain was initiated
at the time of EHEC challenge. Our experimental design
delayed treatment for 24 hours in an attempt to more
closely mimic post-exposure therapy. As a result, pigs in
this study were exposed to intestinal Stx2e prior to treat-
ment with the probiotic. Pigs are known to be extremely
susceptible to intravenous Shiga toxin (LD50 3 ng/kg) [32].
It is likely that the early and continuous exposure to sys-
temic toxin absorbed from the gut initiates an irreversible
Figure 2 Histological confirmation of vascular injury secondary
to Shiga toxemia in ilea (submucosa). Arterioles in control pigs
inoculated with non-pathogenic Escherichia coli lacked lesions
(A). Arteriole from pig inoculated with Shiga toxin producing E. coli
(STEC) strain S1191 and treated with the sham probiotic strain, which
lacked the receptor Shiga toxin mimic (B). Segmental changes within
the tunica media characterized by the presence of karyorrhectic nuclear
debris (arrow) from a myocyte. Arteriole from pig inoculated with STEC
strain S1191 and treated with the receptor mimic probiotic (C). Note
nuclear remnants (arrows) of myocytes within the tunica media, as well
as vacuolization (arrowhead) of the sarcoplasm. Hematoxylin and eosin,
×1000 magnification.
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cascade of events leading to clinical disease development
in some animals. This may represent an obstacle for post-
exposure therapy in human beings because of the delay
between the onset of diarrhea and diagnosis in EHEC
infections [5]. Similarly, when probiotic treatment was
delayed in the mouse model for 24 or 48 hrs, mice were
not protected from death when challenged with the
most virulent EHEC strain [23].
Conclusions
In conclusion, the results of this study show that post-
exposure treatment with a Stx2e-receptor mimic probiotic
is effective at reducing Stx within the gut of a porcine
model of STEC infection. Despite its efficacy at reducing
gut Stx, the probiotic failed to prevent vascular necrosis in
target organs and clinical disease, indicating systemic toxin
absorption still occurred. Further investigation is war-
ranted to determine if adjusting the time of treatment
would have been more effective at ameliorating clinical
STEC disease.
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